Inspire Medical Systems (INSP) UBS Global Healthcare Conference 2025 summary

Key business updates and performance

• Transition from Inspire 4 to Inspire 5 was largely completed in Q3, with over 98% of centers trained and 75% ready for Inspire 5.

• Inspire 5 adoption led to improved patient outcomes, with strong clinical data from Singapore and U.S. commercial use.

• Inventory of Inspire 4 was mostly replaced by Inspire 5 by the end of Q3, with ongoing efforts to finalize the transition.

• Revenue guidance for the year was reaffirmed, with early indication of low double-digit growth (10-11%) for next year.

• Gross margin improved with Inspire 5, and disciplined spending allowed for an increase in EPS guidance.

Operational and commercial strategy

• Focus on community-based hospital systems for growth, with best practices shared from high-performing centers.

• Selective addition of new centers, ensuring readiness and efficiency from launch.

• Commercial organization is shifting toward a 1:1 ratio of territory managers to field clinical reps to improve efficiency.

• Direct-to-consumer (DTC) campaigns are closely tracked for ROI, with conversion rates monitored from web activity to implant.

• Share repurchase program remains active, with $150 million authorization remaining, while prioritizing organic investment and innovation.

Product innovation and clinical outcomes

• Inspire 5 eliminates the need for a pressure-sensing lead, reducing surgical time by 20% and simplifying the procedure for ENTs.

• Inspire 6 is in development, aiming for automated therapy activation and further improved adherence.

• Clinical studies show Inspire 5 offers better synchronization with respiration and improved patient outcomes compared to Inspire 4.

• Recent independent research links Inspire therapy to significant improvements in cardiovascular health and reduced comorbidities.

• These clinical outcomes are expected to further support payer coverage and economic arguments.